To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
DRAVP ID DRAVPa1830
Peptide Name Sequence 52 from Patent US20040229219 A1
Sequence RIQDAIKKLNESYINLKEVGTYEMYVKWPWYVWLLI
Sequence Length 36
Source Mouse hepatitis virus
Target Organism SARS
Patent Type Patent Application
Publication Date 2004-11-18
Patent No US20040229219 A1
Family Info WO/2005/007078
Patent Title Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
Comment
Abstract The present invention relates to peptides that show significant antiviral activity against viral respiratory disease. More particularly, the invention relates to the use of peptides to inhibit membrane fusion and infection by human metapneumovirus and/or human coronavirus in the prevention and treatment of Severe Acute Respiratory Syndrome (SARS) or other severe respiratory diseases caused by theses agents. The peptides are derived from the known amino acid sequence of the fusion glycoproteins of each virus.
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.